Emmaus Life Sciences, Inc. (EMMA)
USD 0.02
(-12.28%)
USD 0.02
(-12.28%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 30.55 Million USD | 32.41% |
| 2022 | 23.07 Million USD | -16.5% |
| 2021 | 27.63 Million USD | 67.49% |
| 2020 | 16.5 Million USD | -6.81% |
| 2019 | 17.7 Million USD | 764.74% |
| 2018 | -2.66 Million USD | 50.79% |
| 2017 | -5.41 Million USD | -2309.97% |
| 2016 | -224.6 Thousand USD | -109.61% |
| 2015 | 2.33 Million USD | 868.53% |
| 2014 | 241.2 Thousand USD | 119.14% |
| 2013 | -1.26 Million USD | -545.53% |
| 2012 | 282.9 Thousand USD | -93.24% |
| 2011 | 4.18 Million USD | 13304.73% |
| 2010 | -31.7 Thousand USD | 96.32% |
| 2009 | -861.8 Thousand USD | 50.25% |
| 2008 | -1.73 Million USD | 69.82% |
| 2007 | -5.74 Million USD | -5007.3% |
| 2006 | -112.39 Thousand USD | -205.06% |
| 2005 | 106.98 Thousand USD | 18.69% |
| 2004 | 90.13 Thousand USD | 510.14% |
| 2003 | 14.77 Thousand USD | 80.38% |
| 2002 | 8190.00 USD | 93.62% |
| 2001 | 4230.00 USD | 332.04% |
| 2000 | -1823.00 USD | 0.0% |
| 1999 | - USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 29.91 Million USD | -0.38% |
| 2024 Q1 | 30.02 Million USD | -1.72% |
| 2023 Q3 | 33.83 Million USD | -4.76% |
| 2023 FY | 30.55 Million USD | 32.41% |
| 2023 Q1 | 25.39 Million USD | -11.81% |
| 2023 Q2 | 35.52 Million USD | 39.87% |
| 2023 Q4 | 30.55 Million USD | -9.69% |
| 2022 FY | 23.07 Million USD | -16.5% |
| 2022 Q2 | 34.43 Million USD | 22.22% |
| 2022 Q1 | 28.17 Million USD | 1.96% |
| 2022 Q3 | 33.05 Million USD | -4.03% |
| 2022 Q4 | 28.79 Million USD | -12.87% |
| 2021 Q2 | 26.05 Million USD | -1.09% |
| 2021 FY | 27.63 Million USD | 67.49% |
| 2021 Q4 | 27.63 Million USD | 1.39% |
| 2021 Q3 | 27.25 Million USD | 4.63% |
| 2021 Q1 | 26.33 Million USD | 59.62% |
| 2020 Q2 | 19.93 Million USD | 15.82% |
| 2020 FY | 16.5 Million USD | -6.81% |
| 2020 Q1 | 17.2 Million USD | -2.81% |
| 2020 Q4 | 16.5 Million USD | 6.31% |
| 2020 Q3 | 15.52 Million USD | -22.12% |
| 2019 FY | 17.7 Million USD | 764.74% |
| 2019 Q2 | -1.82 Million USD | -207.32% |
| 2019 Q3 | 10.21 Million USD | 659.88% |
| 2019 Q4 | 17.7 Million USD | 73.27% |
| 2019 Q1 | -593.9 Thousand USD | 33.98% |
| 2018 Q4 | -899.6 Thousand USD | 66.23% |
| 2018 Q3 | -2.66 Million USD | -29.02% |
| 2018 Q2 | -2.06 Million USD | -12.51% |
| 2018 Q1 | -1.83 Million USD | 11.43% |
| 2018 FY | -2.66 Million USD | 50.79% |
| 2017 Q3 | -5.41 Million USD | -1409.85% |
| 2017 FY | -5.41 Million USD | -2309.97% |
| 2017 Q4 | -2.07 Million USD | 61.73% |
| 2017 Q2 | -358.5 Thousand USD | 78.78% |
| 2017 Q1 | -1.68 Million USD | -74.35% |
| 2016 Q4 | -968.8 Thousand USD | -331.34% |
| 2016 Q1 | 3.53 Million USD | 23.72% |
| 2016 FY | -224.6 Thousand USD | -109.61% |
| 2016 Q2 | 4.14 Million USD | 17.45% |
| 2016 Q3 | -224.6 Thousand USD | -105.41% |
| 2015 Q3 | 2.33 Million USD | 15.63% |
| 2015 FY | 2.33 Million USD | 868.53% |
| 2015 Q4 | 2.85 Million USD | 22.24% |
| 2015 Q2 | 2.02 Million USD | 25.11% |
| 2015 Q1 | 1.61 Million USD | 51.65% |
| 2014 Q2 | -56 Thousand USD | 92.77% |
| 2014 Q1 | -774.1 Thousand USD | -18.82% |
| 2014 Q4 | 1.06 Million USD | 341.46% |
| 2014 FY | 241.2 Thousand USD | 119.14% |
| 2014 Q3 | 241.2 Thousand USD | 530.71% |
| 2013 FY | -1.26 Million USD | -545.53% |
| 2013 Q1 | 6.54 Million USD | -23.21% |
| 2013 Q4 | -651.5 Thousand USD | 48.31% |
| 2013 Q3 | -1.26 Million USD | -121.49% |
| 2013 Q2 | 5.86 Million USD | -10.44% |
| 2012 FY | 282.9 Thousand USD | -93.24% |
| 2012 Q4 | 8.52 Million USD | 2914.95% |
| 2012 Q3 | 282.9 Thousand USD | -95.86% |
| 2012 Q2 | 6.82 Million USD | 15.9% |
| 2012 Q1 | 5.89 Million USD | 16.58% |
| 2011 Q3 | 4.18 Million USD | 108.8% |
| 2011 Q1 | 754.9 Thousand USD | 1080.39% |
| 2011 FY | 4.18 Million USD | 13304.73% |
| 2011 Q2 | 2 Million USD | 165.56% |
| 2011 Q4 | 5.05 Million USD | 20.73% |
| 2010 Q2 | 82.4 Thousand USD | 113.65% |
| 2010 FY | -31.7 Thousand USD | 96.32% |
| 2010 Q4 | -77 Thousand USD | -142.9% |
| 2010 Q1 | -603.6 Thousand USD | 66.87% |
| 2010 Q3 | -31.7 Thousand USD | -138.47% |
| 2009 Q1 | 159 Thousand USD | 120.43% |
| 2009 FY | -861.8 Thousand USD | 50.25% |
| 2009 Q4 | -1.82 Million USD | -111.43% |
| 2009 Q2 | 240.2 Thousand USD | 51.07% |
| 2009 Q3 | -861.8 Thousand USD | -458.78% |
| 2008 Q2 | -2.84 Million USD | 28.79% |
| 2008 Q1 | -3.98 Million USD | 21.34% |
| 2008 FY | -1.73 Million USD | 69.82% |
| 2008 Q4 | -778.3 Thousand USD | 55.07% |
| 2008 Q3 | -1.73 Million USD | 39.03% |
| 2007 Q2 | -6.33 Million USD | -0.02% |
| 2007 Q1 | -6.33 Million USD | -310.8% |
| 2007 FY | -5.74 Million USD | -5007.3% |
| 2007 Q4 | -5.07 Million USD | 11.63% |
| 2007 Q3 | -5.74 Million USD | 9.38% |
| 2006 Q1 | 103.6 Thousand USD | -3.16% |
| 2006 Q3 | -117.81 Thousand USD | -205.73% |
| 2006 Q4 | 3 Million USD | 2650.02% |
| 2006 FY | -112.39 Thousand USD | -205.06% |
| 2006 Q2 | 111.42 Thousand USD | 7.55% |
| 2005 Q4 | 106.98 Thousand USD | 3.81% |
| 2005 Q1 | 96.13 Thousand USD | 6.66% |
| 2005 Q2 | 99.33 Thousand USD | 3.33% |
| 2005 FY | 106.98 Thousand USD | 18.69% |
| 2005 Q3 | 103.05 Thousand USD | 3.74% |
| 2004 FY | 90.13 Thousand USD | 510.14% |
| 2004 Q4 | 90.13 Thousand USD | 33.1% |
| 2004 Q2 | 19.66 Thousand USD | 33.95% |
| 2004 Q1 | 14.68 Thousand USD | -0.61% |
| 2004 Q3 | 67.72 Thousand USD | 244.32% |
| 2003 Q1 | 9148.00 USD | 11.7% |
| 2003 Q2 | 13.24 Thousand USD | 44.79% |
| 2003 Q3 | 13.61 Thousand USD | 2.79% |
| 2003 Q4 | 14.77 Thousand USD | 8.51% |
| 2003 FY | 14.77 Thousand USD | 80.38% |
| 2002 Q3 | 6452.00 USD | -33.17% |
| 2002 Q4 | 8190.00 USD | 26.94% |
| 2002 Q2 | 9655.00 USD | 81.21% |
| 2002 Q1 | 5328.00 USD | 25.96% |
| 2002 FY | 8190.00 USD | 93.62% |
| 2001 Q1 | -467.00 USD | 0.0% |
| 2001 Q2 | 9357.00 USD | 2103.64% |
| 2001 Q4 | 4230.00 USD | -56.8% |
| 2001 FY | 4230.00 USD | 332.04% |
| 2001 Q3 | 9791.00 USD | 4.64% |
| 2000 FY | -1823.00 USD | 0.0% |
| 2000 Q1 | - USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| 1999 Q2 | 100 Thousand USD | 0.0% |
| 1999 Q3 | 100 Thousand USD | 0.0% |
| 1999 Q4 | - USD | -100.0% |
| 1999 FY | - USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 2332466.412% |
| Arch Therapeutics, Inc. | 5.64 Million USD | -440.935% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 28.6% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 12340.205% |
| Rebus Holdings, Inc. | 305 Thousand USD | -9917.705% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 584.636% |
| Qrons Inc. | 351.42 Thousand USD | -8594.267% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -4809.346% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 29.654% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 149815.798% |
| Skye Bioscience, Inc. | -5.72 Million USD | 634.031% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | -93.834% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | -641.958% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -7503.353% |
| SQZ Biotechnologies Company | -36.23 Million USD | 184.315% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | -1262.659% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -3195.347% |
| Mesoblast Limited | 55.85 Million USD | 45.301% |
| Marizyme, Inc. | 18.56 Million USD | -64.543% |
| Genus plc | 190.6 Million USD | 83.97% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | -1266.561% |
| Pharming Group N.V. | 109.8 Million USD | 72.174% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -3451.795% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -2417.036% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -4393.235% |
| ContraFect Corporation | -6.02 Million USD | 607.036% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -22593.276% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -2544.386% |
| IMV Inc. | 7.67 Million USD | -298.33% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | -455.336% |
| MultiCell Technologies, Inc. | 90.04 USD | -33933707.197% |
| ONE Bio Corp. | 9.04 Million USD | -237.985% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 4262.795% |
| RVL Pharmaceuticals plc | 12.94 Million USD | -136.011% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | -2133.527% |
| Q BioMed Inc. | 4.06 Million USD | -652.56% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -2932.005% |
| Biomind Labs Inc. | 711.4 Thousand USD | -4194.899% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 49.536% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -1428.165% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | -138.58% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -8394.065% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -21754.883% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -153692.722% |
| Curative Biotechnology, Inc. | 2.2 Million USD | -1287.569% |
| GB Sciences, Inc. | 1.74 Million USD | -1648.625% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 16724.589% |
| HST Global, Inc. | 96.79 Thousand USD | -31466.332% |
| CSL Limited | 10.52 Billion USD | 99.71% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -14716.431% |
| Halberd Corporation | 144.72 Thousand USD | -21012.347% |
| Enzolytics Inc. | 981.65 Thousand USD | -3012.496% |
| Agentix Corp. | 37.63 Thousand USD | -81093.697% |
| Resverlogix Corp. | 6.45 Million USD | -373.632% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 4639.37% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 101.506% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 164.992% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -332.105% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -1028.03% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 445.637% |
| AVAX Technologies, Inc. | -5.9 Million USD | 617.583% |
| Zenith Capital Corp. | 10.06 Thousand USD | -303496.979% |
| Genscript Biotech Corporation | -1.06 Billion USD | 102.879% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -15144.073% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | -1180.535% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -18472.844% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 166897.685% |
| Kadimastem Ltd | -253.1 Thousand USD | 12171.813% |
| Helix BioMedix, Inc. | -2.57 Million USD | 1288.857% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | -50.69% |
| BioStem Technologies, Inc. | 4.47 Million USD | -583.227% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -15081.81% |
| LadRx Corporation | -2.03 Million USD | 1600.342% |
| Cell Source, Inc. | 9.23 Million USD | -230.959% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -4710.388% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -4710.388% |
| NovAccess Global Inc. | 2.17 Million USD | -1302.547% |
| Affymax, Inc. | -5.59 Million USD | 645.9% |
| Itoco Inc. | 228.3 Thousand USD | -13282.975% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -22367.994% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | -516.381% |
| Mobile Lads Corp. | 484.23 Thousand USD | -6209.785% |
| CytoDyn Inc. | 20.26 Million USD | -50.795% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 4722511.128% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 329759.896% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | -296.496% |
| SYBLEU INC | 473.71 Thousand USD | -6349.883% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | -585.525% |
| International Stem Cell Corporation | 2.59 Million USD | -1079.691% |
| Bioxytran, Inc. | 1.89 Million USD | -1509.025% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -48854.545% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -1300.981% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | -789.75% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | -257.231% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -3854.663% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 2544.32% |
| Neutra Corp. | 52.18 Thousand USD | -58447.148% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 1327.561% |
| PureTech Health plc | -167.19 Million USD | 118.274% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 12575.705% |
| IXICO plc | -4.44 Million USD | 787.443% |
| IntelGenx Technologies Corp. | 13.21 Million USD | -131.137% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 44.296% |
| CSL Limited | 10.52 Billion USD | 99.71% |
| Cellectis S.A. | -43.81 Million USD | 169.728% |